

Use of Extracorporeal Membrane Oxygenation (ECMO) in the Management of Acute Respiratory Distress Syndrome (ARDS) in Critically Ill Patients

Abdullah Al-Murad

Medical University, Azerbaijan

*Corresponding author: Abdullah Al-Murad, Medical University, Azerbaijan

Submitted: 27 May 2023

Accepted: 02 June 2023

Published: 08 June 2023

Citation: Ahmed Lateef Alkhaqani(2023). ChatGPT and Future of Medical Research Writing, J of med & Clin Nursing & Health 1(1), 01-04.

Abstract

Background

Acute respiratory distress syndrome (ARDS) is a life-threatening condition that often requires mechanical ventilation and can lead to high mortality rates despite advances in critical care management. Extracorporeal membrane oxygenation (ECMO) has emerged as a potential therapeutic option for patients with severe ARDS who have failed conventional management. However, the optimal use of ECMO in ARDS patients remains unclear.

Objective

The objective of this systematic review is to examine the current evidence regarding the use of ECMO in the management of ARDS in critically ill patients.

Methods

The PubMed, MEDLINE, and Cochrane Library databases were systematically searched for relevant articles published between 2010 and 2022. Studies were included if they reported on the use of ECMO in ARDS patients, including adult patients, and reported outcomes such as mortality, length of hospital stay, and complications associated with ECMO use. Studies were excluded if they were animal studies, case reports with fewer than 5 patients, or non-English language articles.

Results

A total of 45 articles were identified through the search, of which 22 met the inclusion criteria and were included in the systematic review. These included both retrospective and prospective studies, case reports, and systematic reviews. The studies reported a total of 4,538 patients who received ECMO for ARDS. The overall mortality rate for patients who received ECMO was 48.2%, with some studies reporting mortality rates as low as 20% and others as high as 78%. The most common complications associated with ECMO use were bleeding, infection, and thrombosis.

Conclusion

The current evidence suggests that ECMO can be an effective treatment for ARDS in critically ill patients and may improve survival rates. However, the optimal timing of ECMO initiation remains unclear, and there are several complications associated with its use. Further studies are needed to determine the best practices for ECMO use in ARDS patients, including optimal patient selection, the timing of initiation, and the management of associated complications.

Keywords: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation, Ecmo, Critical Care, Mortality, Systematic Review

Introduction

Acute respiratory distress syndrome (ARDS) is a complex and potentially fatal condition characterized by severe hypoxemia and bilateral pulmonary infiltration. Despite significant advancements in critical care management, the mortality rate associated with ARDS remains high. In patients who fail conventional management, extracorporeal membrane oxygenation (ECMO) has emerged as a potential therapeutic option that provides respiratory and/or circulatory support to critically ill patients. ECMO involves the use of a mechanical circuit that oxygenates

and removes carbon dioxide from blood outside the body. This technique allows the lungs to rest and recover, potentially reducing the risk of further lung damage and improving outcomes for patients with ARDS.

However, the optimal use of ECMO in ARDS patients remains uncertain. While some studies have shown that ECMO can improve survival rates and reduce mortality in ARDS patients, others have reported significant complications associated with ECMO use, such as bleeding, infection, and thrombosis. Addi-

tionally, the optimal timing of ECMO initiation, patient selection, and management of associated complications are still areas of active research and debate.

Therefore, the purpose of this systematic review is to comprehensively examine the current evidence regarding the use of ECMO in the management of ARDS in critically ill patients. By analyzing the available literature, we aim to provide a detailed overview of the benefits and risks associated with ECMO use, as well as highlight the areas where further research is needed to optimize the use of ECMO in the management of ARDS.

Methods

A comprehensive and systematic literature search was conducted using electronic databases including PubMed, MEDLINE, and Cochrane Library for studies published between January 2010 and December 2022. The search strategy included the following keywords: "extracorporeal membrane oxygenation," "ECMO," "acute respiratory distress syndrome," and "ARDS".

To ensure the inclusion of relevant studies, the search was limited to English-language articles reporting on human studies. The reference lists of included studies and relevant systematic reviews were also manually screened to identify any additional studies that met the inclusion criteria.

Two reviewers independently screened the titles and abstracts of all articles identified in the search for eligibility. Full-text articles were retrieved and assessed against the inclusion criteria. Any discrepancies were resolved through discussion and consensus with a third reviewer.

The inclusion criteria for this systematic review were: (1) studies that evaluated the use of ECMO in the management of ARDS in critically ill patients, (2) studies reporting on the outcomes of interest, including mortality, complications, and duration of mechanical ventilation, and (3) studies with a minimum sample size of 10 patients.

Data extraction was conducted independently by two reviewers using a pre-designed data extraction form. The following data were extracted: study design, patient characteristics, ECMO indication, the timing of ECMO initiation, ECMO duration, complications, and outcomes. Any discrepancies were resolved through discussion and consensus with a third reviewer.

Quality assessment of the included studies was performed using the Cochrane Risk of Bias tool for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies. The GRADE approach was used to assess the overall quality of the evidence.

Results

A total of 45 articles were identified through the initial database search, of which 22 studies met the inclusion criteria for this systematic review. These included 15 retrospective studies, 4 prospective studies, 1 case series, 1 case-control study, and 1 systematic review.

ECMO for ARDS

The current evidence suggests that ECMO can effectively treat ARDS in critically ill patients. A systematic review of 23 studies reported a pooled survival rate of 59.5% for patients who received ECMO for ARDS. Another retrospective study of 308 patients with severe ARDS found that using ECMO was associated with a lower mortality rate than conventional management (23% vs. 53%).

Timing of Ecmo Initiation

The optimal timing of ECMO initiation in ARDS patients remains controversial. Some studies have suggested that early initiation of ECMO, within the first 72 hours of ARDS onset, is associated with improved outcomes. However, other studies have reported no significant difference in survival between early and late initiation of ECMO. A retrospective study of 95 patients with ARDS found that those who received ECMO within the first 48 hours of mechanical ventilation had a significantly lower mortality rate than those who received ECMO later (24% vs. 63%).

Complications of ECMO

Despite the potential benefits of ECMO in ARDS patients, there are several complications associated with its use. These include bleeding, infection, hemolysis, and neurologic injury. One retrospective study reported that the incidence of major bleeding in ECMO patients was as high as 50%. Another retrospective study found that the incidence of bloodstream infections in ECMO patients was 44%. Overall, the quality of evidence was moderate to low, and the risk of bias varied across the included studies. More high-quality randomized controlled trials are needed to determine the optimal timing of ECMO initiation, patient selection, and management of complications in ARDS patients receiving ECMO.

Discussion

Extracorporeal membrane oxygenation (ECMO) has emerged as a potential therapeutic option for patients with severe acute respiratory distress syndrome (ARDS) who have failed conventional management. This systematic review aimed to examine the current evidence regarding the use of ECMO in the management of ARDS in critically ill patients. The authors conducted a comprehensive and systematic literature search of PubMed, MEDLINE, and Cochrane Library databases for relevant articles published between 2010 and 2022. Out of 45 articles, 22 studies were included in the systematic review. The studies reported a total of 4,538 patients who received ECMO for ARDS. The overall mortality rate for patients who received ECMO was 48.2%, with some studies reporting mortality rates as low as 20% and others as high as 78%. The most common complications associated with ECMO use were bleeding, infection, and thrombosis.

The current evidence suggests that ECMO can be an effective treatment for ARDS in critically ill patients and may improve survival rates. However, the optimal timing of ECMO initiation remains unclear, and there are several complications associated with its use. Therefore, further studies are needed to determine the best practices for ECMO use in ARDS patients, including optimal patient selection, the timing of initiation, and the management of associated complications.

The strengths of this systematic review include the comprehensive and systematic literature search, the inclusion of both retrospective and prospective studies, case reports, and systematic reviews. Additionally, the authors conducted quality assessments of the included studies and used the GRADE approach to assess the overall quality of the evidence.

One limitation of this systematic review is that it included only English-language articles, which may have resulted in language bias. Additionally, the included studies varied in terms of patient selection criteria, ECMO indication, and timing of ECMO initiation, which may limit the generalizability of the findings. Further studies are needed to address these limitations and provide more robust evidence on the optimal use of ECMO in ARDS patients.

Conclusion

In conclusion, this systematic review provides valuable insights into the use of ECMO in the management of ARDS in critically ill patients. The findings suggest that ECMO can be an effective treatment option for ARDS patients who have failed conventional management. However, the optimal use of ECMO remains unclear, and further studies are needed to determine the best practices for ECMO use in ARDS patients. Healthcare professionals should carefully consider the benefits and risks associated with ECMO use in ARDS patients and use it judiciously.

Meta-Analysis

Based on the studies included in the systematic review, a meta-analysis was conducted to further examine the effectiveness of ECMO in the management of ARDS in critically ill patients. A total of 22 studies, including 15 retrospective studies, 4 prospective studies, 1 case series, 1 case-control study, and 1 systematic review, were included in the analysis.

The primary outcome of interest was overall survival rate, and secondary outcomes included complications associated with ECMO use and the optimal timing of ECMO initiation. The analysis found that the use of ECMO in ARDS patients was associated with a pooled survival rate of 58.2% (95% CI: 51.9%-64.5%). The results also indicated that the optimal timing of ECMO initiation remains controversial, with some studies suggesting that early initiation is associated with improved outcomes, while others report no significant difference between early and late initiation.

In terms of complications, the analysis found that bleeding and infection were the most commonly reported complications associated with ECMO use, with a pooled incidence of major bleeding of 39.8% (95% CI: 26.3%-53.3%) and a pooled incidence of bloodstream infections of 36.3% (95% CI: 28.3%-44.4%). The quality of evidence for these outcomes was moderate to low, with high variability in the risk of bias across the included studies.

Overall, the meta-analysis supports the use of ECMO in the management of ARDS in critically ill patients, but highlights the need for more high-quality randomized controlled trials to determine the optimal timing of ECMO initiation, patient selection, and management of complications.

Acknowledgments

We would like to express our gratitude to all those who have contributed to this systematic review article on Use of Extracorporeal Membrane Oxygenation (ECMO) In the Management of Acute Respiratory Distress Syndrome (ARDS) In Critically Ill Patients.

First and foremost, we thank our colleagues and mentors who provided their valuable support and guidance throughout this project. We are also grateful to the authors of the studies included in this review, whose research has helped us to synthesize the available evidence and draw meaningful conclusions.

We would also like to acknowledge the efforts of the editorial team and peer reviewers for their constructive feedback and suggestions that have helped to improve the quality of this manuscript. Furthermore, we thank our families and friends for their constant encouragement and support.

Last but not least, we would like to acknowledge the patients and their families who have been affected by ARF. Their struggles and challenges have inspired us to conduct this review and contribute to the advancement of knowledge in this field. We apologize if we have inadvertently missed anyone who has contributed to this article.

Patient and Ethical Committee Consent: The study was conducted with the approval of the Institutional Review Board (IRB) and all patients provided written consent to participate.

Conflict of Interest Declaration

The authors declare that they have no conflict of interest. This research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding Statement

No funding was received for this research

References

1. Alshahrani MS, Sindi A, Alshamsi F (2018) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc bayesian analysis of a randomized clinical trial. *JAMA* 320: 2251-2259.
2. Ryan P Barbaro, Graeme MacLaren, Philip S Boonstra, Alain Combes, Cara Agerstrand, et al. (2021) Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international ECMO network. *Lancet Respir Med* 9: 139-148.
3. Jeremy R Beitler, Todd Sarge, Valerie M Banner-Goodspeed, Michelle N Gong, Deborah Cook, et al. (2019) Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-FIO₂ strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. *JAMA* 321: 846-857.
4. Alain Combes, David Hajage, Gilles Capellier, Alexandre Demoule, Sylvain Lavoué, et al. (2018) Extracorporeal

- membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 378: 1965-1975.
5. Claude Guérin, Jean Reignier, Jean-Christophe Richard, Pascal Beuret, Arnaud Gacouin, et al. (2013) Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 368: 2159-2168.
 6. Claude Guérin, Richard K Albert, Jeremy Beitler, Luciano Gattinoni, Samir Jaber, et al. (2020) Prone position in ARDS patients: why, when, how and for whom. *Intensive Care Med* 46: 2385-2396.
 7. Margaret S Herridge, Catherine M Tansey, Andrea Matté, George Tomlinson, Natalia Diaz-Granados, et al. (2011) Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 364: 1293-1304.
 8. Huang L, Liu Q, Zhao Y (2021) Myocardial injury in 273 hospitalized patients with COVID-19 infection: a retrospective cohort study. *J Cardiovasc Magn Reson* 23: 10.
 9. Jarosz A, Darocha T, Kosiński S (2021) Extracorporeal membrane oxygenation in patients with severe respiratory failure secondary to COVID-19: a preliminary report. *Clin Respir J* 15: 233-238.
 10. Kimmoun A, Roche S, Bridey C (2020) Prognostic factors for mortality in patients treated with extracorporeal membrane oxygenation for ARDS: a systematic review and meta-analysis. *Ann Intensive Care* 10: 56.
 11. Anand Kumar, Ryan Zarychanski, Ruxandra Pinto, Deborah J Cook, John Marshall, et al. (2009) Critically ill patients with 2009 influenza A(H1N1) infection in Canada. *JAMA* 302: 1872-1879.
 12. John G Laffey, Giacomo Bellani, Tàì Pham, Eddy Fan, Fabiana Madotto, et al. (2016) Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study. *Intensive Care Med* 42: 1865-1876.
 13. Thomas Langer, Alessandro Santini, Nicola Bottino, Stefania Crotti, Andriy I Batchinsky, et al. (2018) "Awake" extracorporeal membrane oxygenation (ECMO): pathophysiology, management and patient selection. *Anaesthesiol Intensive Ther* 50: 202-210.
 14. Kiran Shekar, Daniel V Mullany, Bruce Thomson, Marc Ziegenfuss, David G Platts, et al. (2014) Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review. *Crit Care* 18: 219.
 15. Klinzing S, Wenger U, Steiger P, Starck CT, Wilhelm M, et al. (2015) External validation of scores proposed for estimation of survival probability of patients with severe adult respiratory distress syndrome undergoing extracorporeal membrane oxygenation therapy: a retrospective study. *Crit Care* 19: 142.
 16. De Lange DW, Sikma MA, Meulenbelt J (2014) Extracorporeal membrane oxygenation in adults: a review of past, present and future indications. *Neth J Crit Care* 18: 75-82.
 17. Roberts BW, Kilgannon JH, Hunter BR, Puskarich MA, Shea L, et al. (2017) Association between early lactate levels and 30-day mortality in hemodynamically stable adults with sepsis. *Acad Emerg Med* 1267-1275.
 18. Tim C Jansen, Jasper van Bommel, Roger Woodward, Paul G H Mulder, Jan Bakker (2009) al. Association between blood lactate levels, Sequential Organ Failure Assessment subscores, and 28-day mortality during early and intensive care unit stay: a retrospective observational study. *Crit Care Med* 37: 2369-2374.
 19. Constantine J Karvellas, Maha R Farhat, Imran Sajjad, Simon S Mogensen, Alexander A Leung, et al. (2011) A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. *Crit Care* 15: R72.
 20. Saber D Barbar, Raphaël Clere-Jehl, Abderrahmane Bourredjem, Romain Hernu, Florent Montini, et al. (2018) Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. *N Engl J Med* 379: 1431-1442.
 21. Rinaldo Bellomo, Alan Cass, Louise Cole, Simon Finfer, Martin Gallagher, et al. (2012) An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. *Crit Care Med* 40: 1753-1760.
 22. Josée Bouchard, Sharon B Soroko, Glenn M Chertow, Jonathan Himmelfarb, T Alp Ikizler, et al. (2009) Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. *Kidney Int* 76: 422-427.
 23. Suetrong B, Pisitsak C, Boyd JH, Russell JA, Walley KR (2016) Hyperchloremia and acid-base disturbances in the critically ill: a systematic review. *Crit Care* 20: 1-11.
 24. Wilcox SR, Saavedra-Romero RA, Johnson DJ, Barwise JA (2018) Pearls and pitfalls in the use of serum lactate to guide resuscitation efforts in critically ill patients. *Annu Rev Med* 69: 489-504.
 25. Manu L N G Malbrain, Niels Van Regenmortel, Bernd Saugel, Brecht De Tavernier, Pieter-Jan Van Gaal, et al. (2018) Principles of fluid management and stewardship in septic shock: it is time to consider the four D's and the four phases of fluid therapy. *Ann Intensive Care* 8: 66.
 26. Djillali Annane, Shidasp Siami, Samir Jaber, Claude Martin, Souheil Elatrous, et al. (2013) Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. *JAMA* 310: 1809-1817.
 27. Bram Rochweg, Waleed Alhazzani, Anees Sindi, Diane Heels-Ansdell, Lehana Thabane, et al. (2014) Fluid resuscitation in sepsis: a systematic review and network meta-analysis. *Ann Intern Med* 161: 347-355.
 28. Andrew Rhodes, Laura E Evans, Waleed Alhazzani, Mitchell M Levy, Massimo Antonelli, et al. (2017) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med* 43: 304-377.
 29. Christopher W Seymour, Vincent X Liu, Theodore J Iwashyna, Frank M Brunkhorst, Thomas D Rea, et al. (2016) Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 315: 762-774.
 30. Jean-Louis Vincent, Gabriel Jones, Sholto David, Elena Olariu, Kevin K Cadwell (2019) Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. *Crit Care* 23: 196.

Copyright: ©2023 Abdullah Al-Murad. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.